Baseline Plasma Osteopontin Protein Elevation Predicts Adverse Outcomes in Hospitalized COVID-19 Patients

Stelvio Tonello, Davide D’Onghia, Daria Apostolo, Erica Matino, Martina Costanzo, Giuseppe Francesco Casciaro, Alessandro Croce, Eleonora Rizzi, Erika Zecca, Anita Rebecca Pedrinelli, Veronica Vassia, Paolo Ravanini, Maria Grazia Crobu, Manuela Rizzi, Raffaella Landi, Luigi Mario Castello, Rosalba Minisini, Gian Carlo Avanzi, Mario Pirisi, Daniele LilleriMattia Bellan, Donato Colangelo, Pier Paolo Sainaghi

Risultato della ricerca: Contributo su rivistaArticolo in rivistapeer review


More than three years have passed since the first case, and COVID-19 is still a health concern, with several open issues such as the lack of reliable predictors of a patient’s outcome. Osteopontin (OPN) is involved in inflammatory response to infection and in thrombosis driven by chronic inflammation, thus being a potential biomarker for COVID-19. The aim of the study was to evaluate OPN for predicting negative (death or need of ICU admission) or positive (discharge and/or clinical resolution within the first 14 days of hospitalization) outcome. We enrolled 133 hospitalized, moderate-to-severe COVID-19 patients in a prospective observational study between January and May 2021. Circulating OPN levels were measured by ELISA at admission and at day 7. The results showed a significant correlation between higher plasma concentrations of OPN at hospital admission and a worsening clinical condition. At multivariate analysis, after correction for demographic (age and gender) and variables of disease severity (NEWS2 and PiO2/FiO2), OPN measured at baseline predicted an adverse prognosis with an odds ratio of 1.01 (C.I. 1.0–1.01). At ROC curve analysis, baseline OPN levels higher than 437 ng/mL predicted a severe disease evolution with 53% sensitivity and 83% specificity (area under the curve 0.649, p = 0.011, likelihood ratio of 1.76, (95% confidence interval (CI): 1.35–2.28)). Our data show that OPN levels determined at the admission to hospital wards might represent a promising biomarker for early stratification of patients’ COVID-19 severity. Taken together, these results highlight the involvement of OPN in COVID-19 evolution, especially in dysregulated immune response conditions, and the possible use of OPN measurements as a prognostic tool in COVID-19.

Lingua originaleInglese
Numero di articolo630
Numero di pubblicazione3
Stato di pubblicazionePubblicato - mar 2023


Entra nei temi di ricerca di 'Baseline Plasma Osteopontin Protein Elevation Predicts Adverse Outcomes in Hospitalized COVID-19 Patients'. Insieme formano una fingerprint unica.

Cita questo